【英語タイトル】Pharmaceutical Glass Packaging Market Size, Share, Industry, Forecast and outlook (2024-2031)
	・商品コード：DAM529NE3313 ・発行会社（調査会社）：DataM Intelligence ・発行日：2024年12月 ・ページ数：約180 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2営業日） ・調査対象地域：グローバル ・産業分野：医療

Global Pharmaceutical Glass Packaging Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030 growing with a CAGR of YY% during the forecast period 2024-2031.

Glass packaging is extensively used in the pharmaceutical industry due to its nonreactive nature and resistance to temperatures. The shelf life of the product and its safety are important in the pharmaceutical industry and hence glass packaging is always preferred to safeguard the contents from oxidation and other reactions to prevent cross-contamination.
Glass packaging enhances the storage time and delivery of drugs which maintains the efficiency of the drug after a few days without any harmful effects. Due to the increasing access to healthcare costs, the demand for generic medicines has increased drastically due to the low costs. hence, the generic drug manufacturers will rely on glass packaging companies for bulk production.

The pharmaceutical sector is experiencing expansion due to causes including the rising prevalence of chronic diseases, an expanding senior population, increased healthcare expenditures by government entities worldwide, and significant initiatives to enhance the affordability of drugs. A May 2022 article indicates that US officials are prioritizing the affordability of prescription drugs since excessively high prices jeopardize consumer access to adequate care.
The expanding patient population and heightened demand for treatments and pharmaceuticals across diverse therapeutic areas globally are prompting major pharmaceutical companies to intensify their research and development efforts to enhance their portfolios and pipeline products. As of March 2022, Sanofi’s R&D pipeline included 91 clinical-stage compounds across multiple therapeutic areas, including oncology, autoimmune disorders, and neurology, with 34 currently in phase III trials or pending approval.
The growing incidence and awareness of chronic diseases, together with accessible treatment choices, are prompting major market participants to intensify their efforts in developing and launching new pharmaceuticals for numerous rare conditions. The expansion of the industry necessitates packaging for treatments of both communicable and non-communicable diseases. Consequently, the need for glass packaging in pharmaceutical manufacturing is rising due to its ability to safeguard medications against damage, biological contamination, and external factors.
The increasing demand for injectable medications is driving the expansion of glass bottles in the pharmaceutical sector. The robust demand for cancer and other high-potency pharmaceuticals, including antibody conjugates and rapidly acting steroids, together the increase in per capita pharmaceutical expenditure, is anticipated to be the principal catalysts for growth.

Market Segmentation

The pharmaceutical glass packaging is segmented based on product, drug type, application and region.

The Vials Segment Accounted for Approximately 45.5% of the Market Share
Vials are expected to hold the largest share in the market due to the rising demand for vaccines and other drugs. Parenteral route drugs are often packed in vials which are highly in demand due to its quick action on the target. Launch of the glass vials by glass packaging companies by collaborating with different pharmaceutical companies are driving the market. For instance, in March 2022, SGD Pharma launched ready-to-use sterile 100ml molded glass vials using SG EZ-fill packaging technology.
Furthermore, in July 2023, Corning Incorporated launched Corning Viridian Vials to expand its glass packaging portfolio. The new technology can improve filling-line efficiency by up to 50% while reducing vial-manufacturing carbon dioxide equivalent (CO2e) emissions by up to 30%.
In October 2023, West Pharmaceutical Services, Inc. collaborated with Corning Incorporated for the launch of the first product. The company holds the distribution rights for Corning Valor Glass vials.